- Price
- $518.68
- Day
- +0.46%
- Mkt Cap
- $22.02B
- 52W Range
- $291.22 – $609.35
- Volume
- 511.9K
- Beta
- 0.56
Find a company by name or ticker and open its page
Breaking news, press releases, and analyst updates.
Most recent articles and analysis covering this company.
Investors interested in Medical - Drugs stocks are likely familiar with United Therapeutics (UTHR) and Sandoz Group AG Sponsored ADR (SDZNY). But which of these two companies is the best option for those looking for undervalued stocks?
Read full article
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that The Lancet has published full results of its ADVANCE OUTCOMES study, available here. Ralinepag has not been approved for use in any indication by the FDA and remains investigational for PAH. Ralinepag reduced the risk of a clinical worsening event by 55% compared with placebo in patients with PAH (hazard ratio 0.45, 95% CI [0.33-0.
Read full article
9,500 shares were disposed of for ~$5.0 million based on a weighted average execution price of $530.42 on July 27, 2026. The transaction represents a 1% reduction in total equity holdings, leaving the insider with ~669,000 shares across direct and indirect accounts.
Read full article
Atika Capital Management LLC purchased a new stake in shares of United Therapeutics Corporation (NASDAQ: UTHR) in the first quarter, according to its most recent 13F filing with the SEC. The fund purchased 12,350 shares of the biotechnology company's stock, valued at approximately $7,323,000. United Therapeutics makes up 0.9% of Atika Capital Management
Read full article
Liquidia's Yutrepia launch is fueling rapid growth, outperforming United Therapeutics on estimates and share gains despite a higher valuation.
Read full article
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Victor Dzau, M.D., to its Board on July 22, 2026.Dr. Dzau recently completed a 12-year tenure as President of the National Academy of Medicine (NAM) and formerly served as Chancellor for Health Affairs at Duke University, President and CEO of the Duke University Health System, and Chairman of Medicine at.
Read full article
United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company's Board of Directors appointed Victor Dzau, M.D.,
Read full article
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release that will be issued on Wednesday, August 5, 2026, at approximately 6:30 a.m. Eastern Time.United Therapeutics will host a public webcast on Wednesday, August 5, 2026, at 9:00 a.m. Eastern Time that will be accessible at https://ir.unither.com/events-and-presentations. A rebroadcast of th.
Read full article
PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.
Read full article
California Public Employees Retirement System increased its position in shares of United Therapeutics Corporation (NASDAQ: UTHR) by 5.9% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 88,289 shares of the biotechnology company's stock after acquiring an additional
Read full article